299 results on '"Sanli, Yasemin"'
Search Results
2. The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors
3. The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study
4. Detecting Amyloid Goiter With 99mTc-PYP SPECT/CT in the Setting of Ankylosing Spondylitis: An Uncommon Involvement of AA Amyloidosis
5. Unusual Metastasis of Signet-Ring Cell Gastric Cancer That Could Not Be Detected With 18F-FDG PET But With 68Ga-FAPI PET/CT
6. Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177Lu-PSMA With No Adrenal Insufficiency
7. FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET/CT
8. Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE
9. 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer
10. The Role of [18F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage
11. 18F-FDG and 68Ga-FAPI-04 PET/CT in Evaluating Clear-Cell Endometrial Cancer
12. Comparison of 2D planar and 3D volumetric methods for estimation of split renal function by 99mTc-DMSA scintigraphy
13. The Role of [18F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage.
14. Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on 90Y Selective Internal Radiation Therapy Planning.
15. Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results
16. Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on 90Y Selective Internal Radiation Therapy Planning
17. Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer
18. The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors
19. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
20. Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification
21. Correction to: Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification
22. Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT
23. The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors.
24. The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study.
25. Influencing factors of lung shunt fraction in transarterial radioembolization treatment
26. Intratumoral Heterogeneity in a Patient With Metastatic Thymic Carcinoma on 18F-FDG, 68Ga-DOTATATE, and 68Ga-FAPI04 PET/CT
27. Fibroblast Activation Protein–Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT
28. CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma
29. 225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience
30. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?
31. Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT
32. Demonstration of in vivo estrogen receptor status with 16α- [18F]fluoro-17ß-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma
33. Precision Medicine and PET–Computed Tomography in Pediatric Malignancies
34. Precision Medicine and PET/Computed Tomography in Melanoma
35. Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
36. Detection of Unusual Peritoneal Metastases of Prostate Cancer With 68Ga–Prostate-Specific Membrane Antigen PET/CT
37. Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT
38. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study
39. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer
40. Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions
41. Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer
42. 68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients
43. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria
44. Unusual Metastasis of Signet-Ring Cell Gastric Cancer That Could Not Be Detected With 18 F-FDG PET But With 68 Ga-FAPI PET/CT.
45. Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters
46. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses
47. Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
48. Intratumoral Heterogeneity in a Patient With Metastatic Thymic Carcinoma on 18F-FDG, 68Ga-DOTATATE, and 68Ga-FAPI04 PET/CT
49. Fibroblast Activation Protein–Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT
50. Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters: A Single-Center Experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.